Akero Therapeutics (AKRO) reported a Q1 net loss Monday of $0.90 per diluted share, unchanged from a year earlier.

Analysts polled by FactSet expected $1.02 loss.

The company did not report any revenue for the quarter ended March 31.

As of March 31, the company said it had $1.13 billion in cash, cash equivalents, and short- and long-term marketable securities, expected to fund operations into 2028.

The company's shares were up 4.1% in recent premarket activity Monday.